Biotech firm Heartseed lands about $26 mln Series B

Tokyo-based Heartseed Inc, a biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure, has raised about $26 million in Series B funding. The investors were SBI Investment, JMDC, Gene Techno Science, Nissay Capital, SMBC Capital and Astellas Venture Management LLC.